



AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:**Claims**

1. (Previously presented) A compound according to the general formula Ia or Ib:




wherein in each,

R1 is H, C₁-C₆ alkyl, cycloalkyl, or C₁-C₄ alkylcycloalkyl;

R2 is C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, 1,3-butadienyl, 1-butane, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, cycloalkyl, C₁-C₄ alkyl-cycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, C_mH_{2m+0-p}Y''_p, CH₂NHCOR₂₁, CH₂NHCSR₂₁, CH₂S(O)_nR₂₁, with n = 0, 1, 2, CH₂SCOR₂₁, CH₂OSO₂-R₂₁, CHO, CH=NOH, CH(OH)R₂₁, -CH=NOR₂₁, -CH=NOCOR₂₁, -CH=NOCH₂CONR₂₁R₂₂, -CH=NOCH(CH₃)CONR₂₁R₂₂, -CH=NOC(CH₃)₂CONR₂₁R₂₂, -CH=N-NHCO-R₂₃, -CH=N-NHCO-CH₂NHCOR₂₁, -

CH=N-O-CH₂NHCOR₂₁, -CH=N-NHCS-R₂₃, -CH=CR₂₄R₂₅ (trans or cis), COOH,



COOR₂₁, CONR₂₁R₂₂, -CH=NR₂₁, -CH=N-NR₂₁R₂₂,

-CH=N-NHSO₂ aryl, or -CH=N-NHSO₂ heteroaryl,

wherein m is 1 to 6, o is 1, p is 1 to 2m+o;

m is 2 to 6, o is -1, p is 1 to 2m+o; or

m is 4 to 6, o is -2, p is 1 to 2m+o;

Y'' is independently from each other selected from the group consisting of halogen, OH,

OR₂₁, NH₂, NHR₂₁, NR₂₁R₂₂, SH and SR₂₁; and

wherein X' is NR₂₁₅, O, or S; and R₂₁₁, R₂₁₂, R₂₁₃, R₂₁₄, R₂₁₅ are independently from each other H or C₁-C₆ alkyl;

R₂₁, R₂₂ are independently from each other C₁-C₁₄ alkyl, C₁-C₁₄ alkanoyl, C₁-C₆ alkylhydroxy, C₁-C₆ alkylamino, C₁-C₆ alkylamino-C₁-C₆ alkyl, C₁-C₆ alkylamino-di-C₁-C₆ alkyl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, aryl, aryloyl, C₁-C₄ alkylaryl, heteroaryl, heteroaryloyl, C₁-C₄ alkylheteroaryl, cycloalkanoyl, C₁-C₄ alkanoylcycloalkyl, heterocycloalkanoyl, C₁-C₄ alkanoylheterocycloalkyl, C₁-C₄ alkanoylaryl, C₁-C₄ alkanoylheteroaryl, or mono- and di-sugars linked through a C atom which would carry an OH group in the sugar, wherein the sugars are independently from each other selected from the group consisting of glucuronic acid and its stereo isomers at all optical atoms, aldopentoses, and aldohexoses, including their desoxy compounds;

R₂₃ independently of R₂₁, is R₂₁, a CH₂-pyridinium salt, or a CH₂-tri-C₁-C₆ alkylammonium salt;


R₂₄ independently of R₂₁, is R₂₁, H, CN, COCH₃, COOH, COOR₂₁, CONR₂₁R₂₂, NH₂, or NHCOR₂₁;

R₂₅ independently of R₂₁, is R₂₁, H, CN, COCH₃, COOH, COOR₂₁, CONR₂₁R₂₂, NH₂, or NHCOR₂₁; or

R24, R25 together are C₄-C₈ cycloalkyl;

R3 is C₂-C₁₄ alkyl, C₂-C₁₄ alkenyl, C₂-C₁₄ alkynyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, wherein the aryls or heteroaryl may be substituted with another aryl, C₁-C₄ alkylaryl, O-aryl, C₁-C₄ alkyl-O-aryl, heteroaryl, C₁-C₄ alkylheteroaryl, O-heteroaryl or C₁-C₄ alkyl-O-heteroaryl,

cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, C_mH_{2m+o}-Y', CH₂NHCOR31, CH₂NHCSR31, CH₂S(O)_nR31, CH₂SCOR31, CH₂OSO₂-R31, CHO, CH=NOH, CH(OH)R31, -CH=NOR31, -CH=NOCOR31, -CH=NOCH₂CONR31R32, -CH=NOCH(CH₃)CONR31R32, -CH=NOC(CH₃)₂CONR31R32, -CH=N-NHCO-R33, -CH=N-NHCO-CH₂NHCOR31, -CH=N-O-CH₂NHCOR31, -CH=N-NHCS-R33, -CH=CR34R35 (trans or cis), COOH, COOR31, CONR31R32, -CH=NR31, -CH=N-



NR31R32, (with X' = NR315, O, S, and R311, R312, R313, R314, R315 being independently from each other H or C₁-C₆ alkyl), -CH=N-NHSO₂ aryl, or -CH=N-NHSO₂- heteroaryl,

wherein m is 2-6, o is 1 or -1, and p is 1 to 2m + o; or

m is 4-6, o is -3 and p is 1 to 2m + o; and

Y' is independently from each other selected from the group consisting of halogen, OH,

OR31, NH₂, NHR31, NR31R32, SH, and SR31; and

wherein n is 0, 1 or 2;

R31, R32 mean independently from each other C₁-C₁₄ alkyl, C₁-C₁₄ alkanoyl, C₁-C₆ alkylhydroxy, C₁-C₆ alkylamino, C₁-C₆ alkylamino-C₁-C₆ alkyl, C₁-C₆ alkylamino-di-C₁-C₆ alkyl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, aryl, aryloyl, C₁-C₄ alkylaryl, heteroaryl, heteroaryloyl, C₁-C₄ alkylheteroaryl, cycloalkanoyl, C₁-C₄ alkanoylcycloalkyl, heterocycloalkanoyl, C₁-C₄ alkanoylheterocycloalkyl, C₁-C₄ alkanoylaryl, C₁-C₄ alkanoylheteroaryl, alkanoylaryl, C₁-C₄ alkanoylheteroaryl, or mono- and di-sugars residues linked through a C atom which would carry an OH group in the sugar, wherein the sugars are independently from each other selected from the group consisting of

glucuronic acid and its stereo isomers at all optical atoms, aldopentoses, and aldohexoses, including their desoxy compounds;

R33 independently of R31, is R31, a CH₂-pyridinium salt, or a CH₂-tri-C₁-C₆ alkylammonium salt;

R34 independently of R21, is R31, H, CN, COCH₃, COOH, COOR21, CONR31R32, NH₂, or NHCOR31;

R35 independently of R31, is R31, H, CN, COCH₃, COOH, COOR31, CONR31R32, NH₂, or NHCOR31; or

R34, R35 together are C₄-C₈ cycloalkyl;

R5 is H, C₁-C₆ alkyl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, aryl, C₁-C₄ alkylaryl, heteroaryl, or C₁-C₄ alkylheteroaryl;

R4, R6, R7 independently from each other are H, C₁-C₆ alkyl, or CO-R41;

R41 independently of R21, is R21;



X is O, S, NH, or N-R8, wherein R8 independently from R5 is R5, or R5 and R8, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group consisting of N, O, and S;

or X-R5 may together be H;

Y is O, S, or NR9, wherein R9 is H or C₁-C₆ alkyl;

or a stereoisomer, tautomer or physically tolerable salt thereof.

2. (Original) The compounds according to claim 1, wherein Formula Ia or Ib adopt the stereochemistry of Formula IIa or IIb




Claims 3-4. (Canceled)

5. (Currently amended) The compound according to claim 1, wherein

R1 is H, C₁-C₅ alkyl, or cycloalkyl;

R2 is C₁-C₅ alkyl, C₁-C₄ alkylaryl, C₂-C₅ alkenyl, heteroaryl, C₁-C₄ alkylheteroaryl, CHF₂, CF₃, polyol side chain, CHOH-CHOH-CHOH-CHOH-CH₃, CHOH-CHOH-CH=CH-CH₃, CH=CH-CHOH-CHOH-CH₃, CH₂Y (Y = F, Cl, Br, I) CH₂Y''' (Y''' = F, Cl, Br, I), CH₂NH₂, CH₂NR₂₁R₂₂, CH₂NHCOR₂₃, CH₂NHCSR₂₃, CH₂SH, CH₂S(O)_nR₂₁, with n = 0, 1, 2, CH₂SCOR₂₁, CH₂OH, CH₂OR₂₁, CH₂OSO₂-R₂₁, CHO, CH(OR₂₁)₂, CH(SR₂₁)₂, CN, CH=NOH, CH=NOR₂₁, CH=NOCOR₂₁, CH=N-NHCO-R₂₃, CH=CR₂₄, R₂₅ (trans or

cis), COOH, COOR₂₁, CONR₂₁R₂₂, -CH=NR₂₁, -CH=N-NR₂₁R₂₂,



wherein X' is NR₂₁₅, O, or S; and R₂₁₁, R₂₁₂, R₂₁₃, R₂₁₄, and R₂₁₅ are independently from each other are H or C₁-C₆ alkyl;

R₂₁, R₂₂ independently from each other are C₁-C₆ alkyl, cycloalkyl, aryl, C₁-C₄ alkylaryl, heteroaryl, or C₁-C₄ alkylheteroaryl;

R₂₃ independently of R₂₁, is R₂₁, a CH₂-pyridinium salt, or a CH₂-tri-C₁-C₆ alkylammonium salt;

R₂₄ independently of R₂₁, is R₂₁, H, CN, COCH₃, COOH, COOR₂₁, CONR₂₁R₂₂, NH₂, or NHCOR₂₁;

R₂₅ independently of R₂₁, is R₂₁, H, CN, COCH₃, COOH, COOR₂₁, CONR₂₁R₂₂, NH₂, or NHCOR₂₁; or

R₂₄, R₂₅ together are C₄-C₈ cycloalkyl;

R₃ is C₂-C₁₄ alkyl, C₂-C₁₄ alkenyl, C₂-C₁₄ alkynyl, aryl, C₁-C₄ alkylaryl, heteroaryl, or C₁-C₄ alkylheteroaryl, wherein the aryls or heteroaryl may be substituted with another aryl, C₁-C₄ alkylaryl, O-aryl, C₁-C₄ alkyl-O-aryl, heteroaryl, C₁-C₄ alkylheteroaryl, O-heteroaryl or C₁-C₄ alkyl-O-heteroaryl;

R₅ is H, C₁-C₃ alkyl, or cycloalkyl;

R₄, R₆, R₇ independently from each other are H, C₁-C₅ alkyl, or CO-R₄₁;

R₄₁ independently of R₂₁, is R₂₁;

X is O, S, NH, or N-R8;

Y is O, S, or NH.


6. (Previously presented) The compound according to claim 1 in the form of an inclusion compound with cyclodextrin.

Claims 7-14. (Canceled)

15. (Previously presented) The compound according to claim 2 wherein

R1 is H, C₁-C₅ alkyl, or cycloalkyl;

R2 is C₁-C₅ alkyl, C₁-C₄ alkylaryl, C₂-C₅ alkenyl, heteroaryl, C₁-C₄ alkylheteroaryl, CHF₂, CF₃, polyol side chain, CHOH-CHOH-CHOH-CHOH-CH₃, CHOH-CHOH-CH=CH-CH₃, CH=CH-CHOH-CHOH-CH₃, CH₂Y''' (Y''' = F, Cl, Br, I), CH₂NH₂, CH₂NR₂₁R₂₂, CH₂NHCOR₂₃, CH₂NHCSR₂₃, CH₂SH, CH₂S(O)_nR₂₁, with n = 0, 1, 2, CH₂SCOR₂₁, CH₂OH, CH₂OR₂₁, CH₂OSO₂-R₂₁, CHO, CH(OR₂₁)₂, CH(SR₂₁)₂, CN, CH=NOH, CH=NOR₂₁, CH=NOCOR₂₁, CH=N-NHCO-R₂₃, CH=CR₂₄, R₂₅ (trans or cis), COOH,



COOR₂₁, CONR₂₁R₂₂, -CH=NR₂₁, -CH=N-NR₂₁R₂₂,

-CH=N-NHSO₂-aryl, -CH=N-NHSO₂-heteroaryl, or CH=N-NHCO-R₂₃,

wherein X' is NR₂₁₅, O, or S; and R₂₁₁, R₂₁₂, R₂₁₃, R₂₁₄, and R₂₁₅ are independently from each other are H or C₁-C₆ alkyl;

R₂₁, R₂₂ independently from each other are C₁-C₆ alkyl, cycloalkyl, aryl, C₁-C₄ alkylaryl, heteroaryl, or C₁-C₄ alkylheteroaryl;

R₂₃ independently of R₂₁, is R₂₁, a CH₂-pyridinium salt, or a CH₂-tri-C₁-C₆ alkylammonium salt;

R24 independently of R21, is R21, H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, or NHCOR21;

R25 independently of R21, is R21, H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, or NHCOR21; or

R24, R25 together are C₄-C₈ cycloalkyl;

R3 is C₂-C₁₄ alkyl, C₂-C₁₄ alkenyl, C₂-C₁₄ alkynyl, aryl, C₁-C₄ alkylaryl, heteroaryl, or C₁-C₄ alkylheteroaryl, wherein the aryls or heteroaryl may be substituted with another aryl, C₁-C₄ alkylaryl, O-aryl, C₁-C₄ alkyl-O-aryl, heteroaryl, C₁-C₄ alkylheteroaryl, O-heteroaryl or C₁-C₄ alkyl-O-heteroaryl;

R5 is H, C₁-C₃ alkyl, or cycloalkyl;

R4, R6, R7 independently from each other are H, C₁-C₅ alkyl, or CO-R41;

R41 independently of R21, is R21;

X is O, S, NH, or N-R8;

Y is O, S, or NH.

16. (Previously presented) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or adjuvant.

17. (Previously presented) A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or adjuvant.